← All trials
NCT04552899
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 29, 2021
- Primary completion
- Feb 15, 2023
- Completion date
- Aug 25, 2023
- First posted
- Sep 17, 2020
- Last posted
- Dec 22, 2020
- Enrollment
- 658
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.